Cambridge, MA, United States of America

Megan Foley

USPTO Granted Patents = 8 


 

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 15(Granted Patents)


Location History:

  • Somerville, MA (US) (2023)
  • Cambridge, MA (US) (2016 - 2024)

Company Filing History:


Years Active: 2016-2024

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Megan Foley

Introduction

Megan Foley is a prominent inventor based in Cambridge, MA, known for her significant contributions to the field of proteostasis. With a total of eight patents to her name, she has made remarkable strides in developing compounds that address various conditions associated with proteostasis dysfunction.

Latest Patents

Megan Foley's latest patents include innovative compounds designed to regulate proteostasis. One of her notable inventions is directed to compounds having specific formulae, including (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX). These compounds, along with their pharmaceutically acceptable salts, prodrugs, and solvates, are aimed at treating conditions linked to proteostasis dysfunction. Another significant patent focuses on proteasome activity enhancing compounds, which also includes various compositions and methods for treatment.

Career Highlights

Throughout her career, Megan has worked with leading companies in the biotechnology sector, including Proteostasis Therapeutics, Inc. and Kineta, Inc. Her work has been instrumental in advancing therapeutic options for patients suffering from proteostasis-related conditions.

Collaborations

Megan Foley has collaborated with notable professionals in her field, including Matthew Cullen and Bradley Tait. These partnerships have contributed to her innovative research and development efforts.

Conclusion

Megan Foley's contributions to the field of proteostasis through her patents and collaborations highlight her role as a leading inventor. Her work continues to pave the way for advancements in medical treatments related to proteostasis dysfunction.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…